Comparable stake leader
FMR LLC
SEC ownership of BIOGEN INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000875045.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
09 Jun 2026
- Public ticker
- BIIB on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
09 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000875045
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BIOGEN INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
09 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 11%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 11%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
11%
PRIMECAP MANAGEMENT CO/CA/
10%
BlackRock, Inc.
8.5%
VANGUARD CAPITAL MANAGEMENT LLC
7.5%
STATE STREET CORP
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
11%
|
$3,406,032,940
16,652,975 shares
|
+$786,506,411 | 29 May 2026 |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
13D/G
Company
|
10%
from 13D/G
|
$2,705,512,094
14,757,607 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
8.5%
from 13D/G
|
$2,928,623,480
15,974,601 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
7.5%
|
$2,014,716,401
10,989,562 shares
|
$0 | 31 Mar 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
5%
from 13D/G
|
$1,314,095,140
7,167,922 shares
|
— | 31 Mar 2026 |
| Caroline Dorsa |
3/4/5
Director
|
0.02%
|
$3,931,673
31,002 shares
|
— | 17 Jun 2025 |
| Eric K. Rowinsky |
3/4/5
Director
|
0.02%
|
$4,737,980
25,844 shares
|
— | 09 Jun 2026 |
| Stephen A. Sherwin |
3/4/5
Director
|
0.01%
|
$2,785,332
15,193 shares
|
— | 09 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,034,229.
Buys
$585
Insiders: 1
Sells
$1,034,815
Insiders: 2
Net
-$1,034,229
Shares: -6,145
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 3
Shares: 6,148
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 3 | 3,408 | $585 | $665,664 | -$665,079 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 2,740 | $0 | $369,150 | -$369,150 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 31 reporting-owner rows connected to BIOGEN INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
31
Largest Forms 3/4/5 holder
Alexander J. Denner
Net 12M change
-$1,034,230
Latest report
09 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Alexander J. Denner | Director | $163,208,552 | Mixed | 15 Jun 2022 | ||
| Michel Vounatsos | Chief Executive Officer, Director | $23,909,726 | Mixed | 18 Feb 2022 | ||
| Susan H. Alexander | EVP Chief Legal Officer | $11,981,713 | Mixed | 13 Feb 2026 | ||
| Stelios Papadopoulos | Director | $9,498,648 | Mixed | 15 Jun 2022 | ||
| Christopher A. Viehbacher | President and CEO, Director | $8,566,813 | Mixed | 13 Feb 2026 | ||
| Eric K. Rowinsky | Director | $4,737,980 | Median | 09 Jun 2026 | ||
| Ginger Gregory | EVP, Human Resources | $4,498,136 | Mixed | 13 Feb 2026 | ||
| Chirfi Guindo | Head of Glob Prod Strat & Com | $4,139,728 | Mixed | 18 Feb 2022 | ||
| Caroline Dorsa | Director | $3,931,673 | Mixed | 17 Jun 2025 | ||
| Nicole Murphy | Head of Pharm Ops and Tech | $3,824,839 | +$585 | +0.02% | Filing P/S | 12 Feb 2026 |
| Richard Mulligan | Director | $3,744,552 | Mixed | 15 Jun 2022 | ||
| Michael R. McDonnell | EVP, Chief Financial Officer | $3,469,566 | Mixed | 10 Feb 2025 | ||
| Nancy Leaming | Director | $3,413,224 | Mixed | 01 Jul 2021 | ||
| Stephen A. Sherwin | Director | $2,785,332 | Median | 09 Jun 2026 | ||
| Alfred Sandrock | Head of Research & Development | $2,521,940 | Mixed | 07 Jun 2021 | ||
| Robin Kramer | Chief Financial Officer | $2,307,886 | Mixed | 13 Feb 2026 | ||
| Rachid Izzar | Head of Global Product Strat. | $2,215,192 | -$300,105 | -12% | Mixed | 13 Feb 2026 |
| Jesus B. Mantas | Director | $2,064,845 | Median | 09 Jun 2026 | ||
| Brian S. Posner | Director | $1,990,200 | Mixed | 31 Dec 2022 | ||
| William A. Hawkins III | Director | $1,900,215 | Median | 09 Jun 2026 |
Recent insider transactions for BIOGEN INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| William Allen Hawkins III | BIIB | Common Stock | Award | 17% | 1,505 | 10,365 | 09 Jun 2026 | Direct | ||
| Stephen A. Sherwin | BIIB | Common Stock | Award | 11% | 1,505 | 15,193 | 09 Jun 2026 | Direct | ||
| Eric K. Rowinsky | BIIB | Common Stock | Award | 6.18% | 1,505 | 25,844 | 09 Jun 2026 | Direct | ||
| Jesus B. Mantas | BIIB | Common Stock | Award | 15.4% | 1,505 | 11,263 | 09 Jun 2026 | Direct | ||
| Susan K. Langer | BIIB | Common Stock | Award | 29.3% | 1,505 | 6,634 | 09 Jun 2026 | Direct | ||
| Monish D. Patolawala | BIIB | Common Stock | Award | 40.6% | 1,505 | 5,215 | 09 Jun 2026 | Direct | ||
| Menelas N. Pangalos | BIIB | Common Stock | Award | 63.5% | 1,505 | 3,875 | 09 Jun 2026 | Direct | ||
| Menelas N. Pangalos | BIIB | Common Stock | Options Exercise | 2,370 | 2,370 | 09 Jun 2026 | Direct | |||
| Menelas N. Pangalos | BIIB | Restricted Stock Unit | Options Exercise | -100% | -2,370 | 0 | 09 Jun 2026 | Direct | ||
| Lloyd Minor | BIIB | Common Stock | Award | 63.5% | 1,505 | 3,875 | 09 Jun 2026 | Direct | ||
| Maria C. Freire | BIIB | Common Stock | Award | 29.4% | 2,005 | 8,820 | 09 Jun 2026 | Direct | ||
| Adam Keeney | BIIB | Common Stock | Tax liability | -6.67% | -455 | 6,365 | 01 May 2026 | Direct | ||
| Adam Keeney | BIIB | Common Stock | Options Exercise | 16% | 939 | 6,820 | 01 May 2026 | Direct | ||
| Adam Keeney | BIIB | Restricted Stock Unit | Options Exercise | -100% | -939 | 0 | 01 May 2026 | Direct | ||
| Sean Godbout | BIIB | Common Stock | Tax liability | -3.87% | -54 | 1,342 | 01 Apr 2026 | Direct | ||
| Sean Godbout | BIIB | Common Stock | Options Exercise | 14.9% | 181 | 1,396 | 01 Apr 2026 | Direct | ||
| Sean Godbout | BIIB | Restricted Stock Unit | Options Exercise | -33.2% | -181 | 364 | 01 Apr 2026 | Direct | ||
| Christopher A. Viehbacher | BIIB | Restricted Stock Unit | Award | 38,015 | 38,015 | 13 Feb 2026 | Direct | |||
| Priya Singhal | BIIB | Restricted Stock Unit | Award | 10,560 | 10,560 | 13 Feb 2026 | Direct | |||
| Nicole Murphy | BIIB | Restricted Stock Unit | Award | 10,560 | 10,560 | 13 Feb 2026 | Direct | |||
| Robin Kramer | BIIB | Restricted Stock Unit | Award | 8,450 | 8,450 | 13 Feb 2026 | Direct | |||
| Adam Keeney | BIIB | Restricted Stock Unit | Award | 8,025 | 8,025 | 13 Feb 2026 | Direct | |||
| Rachid Izzar | BIIB | Restricted Stock Unit | Award | 7,390 | 7,390 | 13 Feb 2026 | Direct | |||
| Jane Grogan | BIIB | Restricted Stock Unit | Award | 8,450 | 8,450 | 13 Feb 2026 | Direct | |||
| Ginger Gregory | BIIB | Restricted Stock Unit | Award | 8,025 | 8,025 | 13 Feb 2026 | Direct | |||
| Sean Godbout | BIIB | Restricted Stock Unit | Award | 1,800 | 1,800 | 13 Feb 2026 | Direct | |||
| Susan H. Alexander | BIIB | Restricted Stock Unit | Award | 8,450 | 8,450 | 13 Feb 2026 | Direct | |||
| Nicole Murphy | BIIB | Common Stock | Purchase | 0.02% | $585 | $195.04 | 3 | 19,611 | 12 Feb 2026 | Direct |
| Priya Singhal | BIIB | Common Stock | Sale | -24.8% | $531,548 | $199.83 | -2,660 | 8,043 | 09 Feb 2026 | Direct |
| Christopher A. Viehbacher | BIIB | Common Stock | Tax liability | -34.2% | -10,980 | 21,095 | 06 Feb 2026 | Direct | ||
| Christopher A. Viehbacher | BIIB | Common Stock | Options Exercise | 202.4% | 24,461 | 36,548 | 06 Feb 2026 | Direct | ||
| Christopher A. Viehbacher | BIIB | Restricted Stock Unit | Options Exercise | -73.1% | -24,461 | 9,009 | 06 Feb 2026 | Direct | ||
| Priya Singhal | BIIB | Common Stock | Tax liability | -24.9% | -2,468 | 7,432 | 06 Feb 2026 | Direct | ||
| Priya Singhal | BIIB | Common Stock | Options Exercise | 132.3% | 6,900 | 12,115 | 06 Feb 2026 | Direct | ||
| Priya Singhal | BIIB | Restricted Stock Unit | Options Exercise | -75.7% | -6,900 | 2,217 | 06 Feb 2026 | Direct | ||
| Nicole Murphy | BIIB | Common Stock | Tax liability | -17.9% | -3,339 | 15,307 | 06 Feb 2026 | Direct | ||
| Nicole Murphy | BIIB | Common Stock | Options Exercise | 71% | 8,725 | 21,016 | 06 Feb 2026 | Direct | ||
| Nicole Murphy | BIIB | Restricted Stock Unit | Options Exercise | -100% | -8,725 | 0 | 06 Feb 2026 | Direct | ||
| Robin Kramer | BIIB | Common Stock | Tax liability | -15.3% | -1,543 | 8,528 | 06 Feb 2026 | Direct | ||
| Robin Kramer | BIIB | Common Stock | Options Exercise | 66.4% | 5,003 | 12,535 | 06 Feb 2026 | Direct | ||
| Robin Kramer | BIIB | Restricted Stock Unit | Options Exercise | -100% | -5,003 | 0 | 06 Feb 2026 | Direct | ||
| Adam Keeney | BIIB | Common Stock | Tax liability | -30.6% | -1,583 | 3,597 | 06 Feb 2026 | Direct | ||
| Adam Keeney | BIIB | Common Stock | Options Exercise | 283% | 5,080 | 6,875 | 06 Feb 2026 | Direct | ||
| Adam Keeney | BIIB | Restricted Stock Unit | Options Exercise | -73.8% | -5,080 | 1,802 | 06 Feb 2026 | Direct | ||
| Rachid Izzar | BIIB | Common Stock | Tax liability | -21.6% | -2,038 | 7,399 | 06 Feb 2026 | Direct | ||
| Rachid Izzar | BIIB | Common Stock | Options Exercise | 140.7% | 6,889 | 11,786 | 06 Feb 2026 | Direct | ||
| Rachid Izzar | BIIB | Restricted Stock Unit | Options Exercise | -100% | -6,889 | 0 | 06 Feb 2026 | Direct | ||
| Jane Grogan | BIIB | Common Stock | Tax liability | -26.4% | -991 | 2,769 | 06 Feb 2026 | Direct | ||
| Jane Grogan | BIIB | Common Stock | Options Exercise | 235.4% | 3,258 | 4,642 | 06 Feb 2026 | Direct | ||
| Jane Grogan | BIIB | Restricted Stock Unit | Options Exercise | -70.2% | -3,258 | 1,385 | 06 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.